HN30.F Restart Life Sciences Corp.
- Market cap
- EUR 2.69M
- P/E
- -
- P/B
- 2.73x
- ROE
- -202.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is HN30.F undervalued?
Graham numberThe Graham number of Restart Life Sciences Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Restart Life Sciences Corp. fundamental analysis
No fundamental analysis for Restart Life Sciences Corp. yet.
Restart Life Sciences Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Restart Life Sciences Corp.
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company in Canada. It engages in research and development of psilocybin; and fund food-related research initiative in support of its expanding portfolio of consumer health and wellness products. The company has collaboration with the University of Manitoba's Richardson Centre for food technology and research (RCFTR) to support a series of food-related scientific studies, including the developm…
Full company profileRestart Life Sciences Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Restart Life Sciences Corp. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 931K |
| Gross Profit | 0.00 | 0.00 | - | - | - | 385K |
| Operating Income | -2.93M | -1.94M | -1.26M | -659K | -1.35M | -2.41M |
| EBITDA | - | -1.93M | -1.26M | -656K | -1.34M | -2.62M |
| Net Income | -2.68M | -2.47M | -1.22M | 225K | -1.39M | -2.69M |
| EPS | -0.24 | -0.17 | -0.08 | 0.01 | -0.03 | -0.04 |
| Balance Sheet | ||||||
| Total Assets | 881K | 297K | 31.1K | 190K | 1.77M | 1.90M |
| Total Liabilities | 422K | 255K | 842K | 489K | 480K | 579K |
| Shareholders' Equity | 459K | 41.3K | -811K | -299K | 1.29M | 1.32M |
| Cash & Short-term Investments | 219K | 267K | 8.09K | 11.3K | 1.60M | 637K |
| Cash Flow | ||||||
| Operating Cash Flow | -1.95M | -2.41M | -278K | -71.8K | -717K | -1.15M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.95M | -2.41M | -278K | -71.8K | -717K | -1.15M |
| Ratios | ||||||
| ROE | -584.8% | -5,964.3% | - | - | -108.0% | -202.7% |
| ROA | -304.7% | -830.9% | -3,942.2% | 118.0% | -78.7% | -141.1% |
| Net Profit Margin | - | - | - | - | - | -288.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Restart Life Sciences Corp. dividends
Restart Life Sciences Corp. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:2 on Jan 24, 2025.
Who owns Restart Life Sciences Corp.
- Insiders 4.96%
- Institutions 0.00%
- Public & others 95.04%
- Shares outstanding 62.5M
- Free float 57.2M
Restart Life Sciences Corp. company profile
- Company name
- Restart Life Sciences Corp.
- Ticker
- HN30.F
- ISIN
- CA76134J2065
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 700-838 West Hasting Street, Vancouver, BC, Canada, V6C 0A6
- Phone
- 778 819 0244
- Website
- restartlife.co
About Restart Life Sciences Corp.
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company in Canada. It engages in research and development of psilocybin; and fund food-related research initiative in support of its expanding portfolio of consumer health and wellness products. The company has collaboration with the University of Manitoba's Richardson Centre for food technology and research (RCFTR) to support a series of food-related scientific studies, including the development across various product lines, including BrainQ, BrainBalls, and Holy Crap. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.
Restart Life Sciences Corp. management
4- Mr. Steve LoutskouPresident, CEO & Executive Chairman
- Ms. Inez HoChief Financial Officer · born 1984
- Dr. Aylia Mohammadi B.Sc., M.Sc., Ph.D.President & Chief Scientific Officer of Nova Mentis Biotech Corp. · born 1980
- Ms. Kelly PladsonCorporate Secretary · born 1983